IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.060
AS - Asia 3.001
EU - Europa 1.987
SA - Sud America 459
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 20.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.965
SG - Singapore 1.449
CN - Cina 564
RU - Federazione Russa 404
BR - Brasile 383
HK - Hong Kong 353
IE - Irlanda 299
IT - Italia 278
VN - Vietnam 253
DE - Germania 238
FR - Francia 171
GB - Regno Unito 129
UA - Ucraina 119
SE - Svezia 101
JP - Giappone 86
FI - Finlandia 82
IN - India 64
CA - Canada 58
KR - Corea 46
PL - Polonia 32
ID - Indonesia 28
NL - Olanda 28
AR - Argentina 27
ES - Italia 27
AT - Austria 22
MX - Messico 21
TR - Turchia 21
BD - Bangladesh 20
ZA - Sudafrica 17
IQ - Iraq 15
KG - Kirghizistan 12
MY - Malesia 12
CO - Colombia 11
EG - Egitto 11
EC - Ecuador 10
MA - Marocco 10
CL - Cile 9
PK - Pakistan 9
UZ - Uzbekistan 9
BE - Belgio 8
DZ - Algeria 8
KZ - Kazakistan 8
PH - Filippine 8
PY - Paraguay 8
AU - Australia 7
IL - Israele 7
RO - Romania 7
CH - Svizzera 6
CZ - Repubblica Ceca 6
EU - Europa 6
GR - Grecia 6
VE - Venezuela 6
ET - Etiopia 5
JO - Giordania 5
LT - Lituania 5
NP - Nepal 5
TH - Thailandia 5
TW - Taiwan 5
KE - Kenya 4
LV - Lettonia 4
UY - Uruguay 4
AZ - Azerbaigian 3
LB - Libano 3
MN - Mongolia 3
SA - Arabia Saudita 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GH - Ghana 2
HU - Ungheria 2
IR - Iran 2
JM - Giamaica 2
PA - Panama 2
TN - Tunisia 2
VC - Saint Vincent e Grenadine 2
AD - Andorra 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
MD - Moldavia 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
RE - Reunion 1
RS - Serbia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
Totale 20.586
Salva come PNG Salva come JPEG
Città #
Wilmington 3.384
Houston 3.230
Woodbridge 2.183
Fairfield 872
Singapore 777
Ashburn 693
Chandler 510
Seattle 394
San Jose 365
Hong Kong 350
Cambridge 307
Ann Arbor 301
Dublin 282
Beijing 231
Medford 211
Dallas 151
Council Bluffs 145
Santa Clara 133
The Dalles 129
Dearborn 102
Lawrence 101
New York 97
Los Angeles 96
Lauterbourg 86
Jacksonville 80
Tokyo 79
Hanoi 73
Munich 73
Ho Chi Minh City 70
Moscow 67
San Diego 64
Rome 55
Buffalo 52
Helsinki 41
São Paulo 36
London 33
Redondo Beach 30
Zhengzhou 30
Nuremberg 29
Redwood City 24
Chennai 23
Shanghai 23
Toronto 21
Boardman 20
Milan 20
Brooklyn 19
Jakarta 19
Orem 19
Denver 18
Menlo Park 18
Seoul 18
Atlanta 15
North Bergen 15
Falls Church 14
Kraków 14
Lappeenranta 14
San Francisco 14
Warsaw 14
Washington 14
Chicago 13
Esslingen am Neckar 13
Guangzhou 13
Pune 13
Montreal 12
Norwalk 12
Stockholm 12
Ankara 11
Johannesburg 11
Manchester 11
Poplar 11
Da Nang 10
Frankfurt am Main 10
Mountain View 10
Phoenix 10
Columbus 9
Saint Petersburg 9
Belo Horizonte 8
Boston 8
Del Norte 8
Hefei 8
Mexico City 8
Nanjing 8
Perugia 8
Porto Alegre 8
Salt Lake City 8
Vienna 8
Brussels 7
Curitiba 7
Detroit 7
Haiphong 7
Mülheim 7
Ottawa 7
Turin 7
Alexandria 6
Amsterdam 6
Dhaka 6
Nanchang 6
Newark 6
North Charleston 6
Rio de Janeiro 6
Totale 16.659
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 530
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 482
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 466
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 440
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 438
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 436
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 436
Brodalumab for the treatment of psoriasis 430
Tildrakizumab for treating psoriasis 423
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 418
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 406
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 402
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 397
Tofacitinib for the treatment of psoriasis 395
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 394
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 391
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 369
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 366
A safety evaluation of guselkumab for the treatment of psoriasis 363
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 348
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 340
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 340
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 320
Photo-recall cutaneous reaction to gemcitabine 318
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 309
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 300
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 295
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 288
Pharmacotherapeutic management of psoriasis in adolescents and children 267
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 265
Skin immunity and its dysregulation in psoriasis 257
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 254
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 246
Successful treatment of psoriatic crumbly nails with ustekinumab 240
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 222
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 220
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 216
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 210
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 204
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 201
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 193
Efalizumab 183
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 177
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 176
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 176
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 175
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 158
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 154
Genetic markers predictive of clinical response to biological drugs in psoriasis. 144
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 139
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 139
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 138
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 137
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 133
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 131
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 130
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 128
Italian guidelines in diagnosis and treatment of alopecia areata 125
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 121
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 120
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 116
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 116
Clinical severity instruments 116
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 110
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 110
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 106
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 105
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 101
Long-term efficacy of adalimumab in generalized pustular psoriasis 98
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 96
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 95
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 94
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 91
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 90
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 90
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 89
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes 89
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 88
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 88
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 86
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 84
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 84
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 84
Linear psoriasis following the typical distribution of the sciatic nerve 83
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 82
Quality of life and psychological impact in patients with atopic dermatitis 82
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 81
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 80
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 80
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 79
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 79
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 79
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 78
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 74
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 74
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 74
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 74
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 71
Genetic variations in IL6 and IL12B as protective markers for psoriasis 69
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 68
Totale 20.152
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021340 0 0 0 0 0 0 0 0 0 166 124 50
2021/20221.134 65 101 107 35 29 52 139 42 84 87 84 309
2022/20231.216 142 125 104 117 78 299 91 61 102 21 45 31
2023/2024524 41 14 22 13 65 121 68 64 4 8 27 77
2024/20252.387 121 453 268 238 33 231 152 99 221 209 187 175
2025/20263.944 305 184 582 324 376 157 629 476 512 399 0 0
Totale 21.250